<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405171</url>
  </required_header>
  <id_info>
    <org_study_id>SIROCCO</org_study_id>
    <nct_id>NCT00405171</nct_id>
  </id_info>
  <brief_title>Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia</brief_title>
  <official_title>Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <brief_summary>
    <textblock>
      Dyslipidemia and coronary heart disease (CHD) are increasingly recognized in persons with
      human immunodeficiency virus (HIV) infection. Many antiretrovirals, including efavirenz
      (EFV), are associated with increases in serum lipids. The investigators investigated whether
      stopping EFV and replace EFV by nevirapine can reduce significantly Low-Density Lipoprotein
      cholesterol, while keeping virologic control of HIV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in LDL cholesterol between baseline and week 52</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Antiretroviral Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz
             for at least 6 months

          -  plasma HIV RNA&lt;400 cp/ml during the previous 4 months on 2 occasions 14 days apart

          -  Severe dyslipidemia with Low-Density Lipoprotein cholesterol (LDL-c) &gt;3.4 mmol/L in
             the presence of at least one of the 3 following coronary heart disease (CHD) risk
             factors: age&gt;45 among males or age&gt;55 among females, hypertension, current smoking,
             family history of CHD

          -  Low-Density Lipoprotein cholesterol (LDL-c)&gt;4.1 mmol/L regardless of CHD risk factors.

        Exclusion Criteria:

          -  Protease inhibitors use within the previous 6 months,

          -  Prior exposure to nevirapine

          -  Asparate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5N if hepatitis
             virus B or C were negative

          -  AST or ALT&gt;1.25N if hepatitis virus B or C were positive

          -  Fasting glycemia&gt;1.26g/L,

          -  Current CHD

          -  Triglycerides&gt;4.6 mmol/L

          -  Introduction of lipid lowering drugs, corticoïds, retinoïds and betablockers within
             the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques Parienti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renaud Verdon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Côte de Nacre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Côte de Nacre University hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Parienti JJ, Peytavin G, Reliquet V, Verdon R, Coquerel A. Pharmacokinetics of the treatment switch from efavirenz to nevirapine. Clin Infect Dis. 2010 Jun 1;50(11):1547-8. doi: 10.1086/652718.</citation>
    <PMID>20433360</PMID>
  </reference>
  <results_reference>
    <citation>Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R; SIROCCO study team. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007 Jul 15;45(2):263-6. Epub 2007 Jun 6.</citation>
    <PMID>17578790</PMID>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <keyword>Efavirenz</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

